Werewolf Therapeutics, Inc.

HOWL Nasdaq SEC CIK 1785530
Follow Werewolf Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$9.9M +39.7% vs same quarter last year
EPS, diluted −$0.20 +44.4% vs same quarter last year
Operating cash flow −$9M +40.8% vs same quarter last year
Operating income −$10.1M +36.1% vs same quarter last year
Net income by quarter
−$20.4M
−$18.1M
−$18M
−$16.4M
−$8.4M
−$13.5M
$3.7M
−$9.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$80M−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$60.8M
FY24−$70.5M
FY23−$37.4M
FY22−$53.8M
FY21−$50M
FY20−$15M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$60.3M
FY24−$56.4M
FY23−$33.4M
FY22−$44.2M
FY21−$43.4M
FY20−$19.2M
FY19-